Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's ($GSK) China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye. As Reuters reports, that extra surveillance helped turn up failures to comply with expense rules, leading to the firing of some staffers for malpractice. "Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate," a Glaxo spokesman told the news service. More